US 12,467,040 B2
Mutant Taq polymerase for increased salt concentration or body fluids
Zhenyu Zhu, Lynnfield, MA (US); Dapeng Sun, Lexington, MA (US); and Weiling Peng, Farmington, CT (US)
Assigned to ABclonal Science, Inc., Woburn, MA (US)
Filed by AbClonal Science Inc., Woburn, MA (US)
Filed on Sep. 28, 2021, as Appl. No. 17/487,643.
Application 17/487,643 is a continuation of application No. 16/813,488, filed on Mar. 9, 2020, granted, now 11,168,312, issued on Nov. 9, 2021.
Claims priority of provisional application 62/816,196, filed on Mar. 10, 2019.
Prior Publication US 2023/0094503 A1, Mar. 30, 2023
Prior Publication US 2023/0332117 A9, Oct. 19, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/12 (2006.01)
CPC C12N 9/1252 (2013.01) [C12Y 207/07007 (2013.01)] 2 Claims
OG exemplary drawing
 
1. A mutant Taq polymerase which is active in a whole blood, plasma or serum, or in a PCR mixture which includes KCl at a concentration of 10 to 110 mM, comprising one of the following amino acid mutations preceding an even-numbered sequence identification number but wherein each said amino acid sequence does not include the 6-membered histidine tag at its C-terminus and the six immediately preceding Glycine and Serine amino acids shown in each said amino acid sequence, and wherein a DNA encoding each said amino acid sequence is the odd-numbered sequence identification number following each said even-numbered sequence identification number:
V737S SEQ ID NOS: 438-439; E745K SEQ ID NOS: 466-467; M765S SEQ ID NOS: 468-469; E774K SEQ ID NOS: 470-471; L781S SEQ ID NOS: 472-473; A791F SEQ ID NOS: 474-475; E805K SEQ ID NOS: 476-477; L813S SEQ ID NOS: 478-479; Q534R SEQ ID NOS: 312-313; E537K SEQ ID NOS: 314-315; 1546S SEQ ID NOS: 356-357; and D547R SEQ ID NOS: 358-359.